UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

PloS one, 2018-03, Vol.13 (3), p.e0191461-e0191461

2018

Volltextzugriff (PDF)

Treatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma

Journal of health economics and outcomes research (Online), 2020, Vol.7 (2), p.148-157

2020

Volltextzugriff (PDF)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical cancer research, 2021-11, Vol.27 (22), p.6124-6134

2021

Volltextzugriff (PDF)

Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary

Clinical advances in hematology & oncology, 2017-03, Vol.15 Suppl 3 (3), p.21-23

Fowler, Nathan H

2017

Volltextzugriff (PDF)

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis

Oncotarget, 2018-06, Vol.9 (48), p.28897-28902

2018

Volltextzugriff (PDF)

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2‐microglobulin level in patients with diffuse large b‐cell lymphoma: a new prognostic model

British journal of haematology, 2016-10, Vol.175 (2), p.290-299

2016

Volltextzugriff (PDF)

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Leukemia & lymphoma, 2020-10, Vol.61 (12), p.2985-2989

2020

Volltextzugriff (PDF)

R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma

Clinical advances in hematology & oncology, 2014-09, Vol.12 (9), p.608-610

Fowler, Nathan H

2014

Volltextzugriff (PDF)

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Cell reports. Medicine, 2023-08, Vol.4 (8), p.101158-101158, Article 101158

2023

Volltextzugriff (PDF)

Pretreatment SUV max may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Leukemia & lymphoma, 2020-06, Vol.61 (6), p.1380-1387

2020

Volltextzugriff (PDF)

Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma

P&T (Lawrenceville, N.J.), 2011-09, Vol.36 (9), p.590-598

Fowler, Nathan H

2011

Volltextzugriff (PDF)

Unmet needs in the treatment of mantle cell lymphoma

Clinical advances in hematology & oncology, 2013-11, Vol.11 (11 Suppl 18), p.1-19

2013

Volltextzugriff (PDF)

Integrating emerging treatment options in mantle cell lymphoma

Clinical advances in hematology & oncology, 2013-12, Vol.11 (12 Suppl 19), p.1-15

2013

Volltextzugriff (PDF)

Integrated Genomic and Transcriptomic Analysis Provides Molecular Characterization of Distinct Clonal Evolution Pathways during Follicular Lymphoma Transformation

Blood, 2022-11, Vol.140 (Supplement 1), p.6681-6682

2022

Volltextzugriff (PDF)

Patient Profile and Treatment Patterns in a Commercially Insured Population with Follicular Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.5880-5880

2019

Volltextzugriff (PDF)

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Blood, 2019-11, Vol.134 (Supplement_1), p.5252-5252

2019

Volltextzugriff (PDF)

Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study

Blood, 2021-11, Vol.138 (Supplement 1), p.3533-3533

2021

Volltextzugriff (PDF)

Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.3532-3532

2021

Volltextzugriff (PDF)

The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.45-45

2021

Volltextzugriff (PDF)

Abstract 1441: Predictors of treatment response in a preoperative window of opportunity trial of nivolumab in resectable squamous cell carcinoma of the head and neck

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1441-1441

2021

Volltextzugriff (PDF)

Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin

Blood, 2022-11, Vol.140 (Supplement 1), p.3721-3723

2022

Volltextzugriff (PDF)

Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.4502-4503

2022

Volltextzugriff (PDF)

Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.9228-9230

2022

Volltextzugriff (PDF)

O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)

Annals of oncology, 2021-07, Vol.32, p.S293-S293

2021

Volltextzugriff (PDF)

Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.414-414

2019

Volltextzugriff (PDF)

1 – 25 von 182

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(172)

Publikationsform

Sprache

Englisch
(182)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Humans
(11)
Physical Sciences
(9)
Technology
(6)
Engineering
(5)
Follicular Lymphoma
(5)
Integrated Circuits
(5)
Tomography
(5)
Adult
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Climate Change
(4)
Computed Tomography
(4)
Engineering, Electrical & Electronic
(4)
Geology
(4)
Geosciences, Multidisciplinary
(4)
Hydrology
(4)
Retrospective Studies
(4)
Water Resources
(4)
Electron Beams
(3)
Female
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

Treatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2‐microglobulin level in patients with diffuse large b‐cell lymphoma: a new prognostic model

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Pretreatment SUV max may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma

Unmet needs in the treatment of mantle cell lymphoma

Integrating emerging treatment options in mantle cell lymphoma

Integrated Genomic and Transcriptomic Analysis Provides Molecular Characterization of Distinct Clonal Evolution Pathways during Follicular Lymphoma Transformation

Patient Profile and Treatment Patterns in a Commercially Insured Population with Follicular Lymphoma

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study

Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma

The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

Abstract 1441: Predictors of treatment response in a preoperative window of opportunity trial of nivolumab in resectable squamous cell carcinoma of the head and neck

Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin

Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)

Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma

Aktive Filter

Suchergebnisse filtern